Nanosonics (ASX:NAN), a leader in infection prevention, announces it has been granted clearance from the US FDA for its latest trophon2 innovation, enabling the company to commercially launch trophon3 and trophon2 Plus, a software upgrade package for existing trophon2 users, in the US.
The company said trophon3, a software for ultrasound disinfection, delivers a range of new benefits to customers while maintaining a high standard in clinical efficacy for patient safety. It said the innovation is over 40 per cent faster than previous generations. It has expanded digital integration capabilities and offers the widest traceability capabilities in the ultrasound reprocessing market, including new digital traceability through customers’ DICOM imaging database systems, the international standard for medical imaging data. Fully programmable and adaptable, trophon3 can be customised to suit a range of customer workflows, enhancing efficiency while delivering consistent, reliable disinfection in a safe, effective, and environmentally friendly way.
With approximately 20,000 trophon2 devices globally, this new package represents a significant software upgrade opportunity, it said.
“The FDA clearance and USA launch of trophon3 and trophon2 Plus mark an important milestone for Nanosonics. These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades,” said Michael Kavanagh, CEO and President.